CJD Overview Bob Will, National CJD Surveillance Unit, Edinburgh, UK Associazione Italiana Encefalopatie da Prion Milano 3 Ottobre 2009.

Slides:

Advertisements

Similar presentations

Distinctive characteristics

Advertisements

FDA Workshop “Data and Data Needs to Advance Risk Assessment for Emerging Infectious Diseases for Blood and Blood Products” November 29, 2011, Gaithersburg.

Prion Disease Transmissible spongiform encephalopathy (TSE)

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.

Removal of Prions by Plasma Fractionation Processes

Bovine Spongiform Encephalopathy (BSE) in Canada Pedro Piccardo, MD Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research.

Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.

1 Donor Deferral / Ineligibility for Time Spent in Saudi Arabia to Reduce Risk of vCJD Transmitted by Blood and Blood Products and by Human Cells, Tissues.

PRION DISEASES BLOOD INFECTIVITY ISSUES Richard Knight NCJDSU.

Predicting an Epidemic A Quantitative Assessment of TSE Sampling Data to Predict Outbreak Magnitude Aspen Shackleford HONR299J.

Analysis to Inform Decisions: Evaluating BSE Joshua Cohen and George Gray Harvard Center for Risk Analysis Harvard School of Public Health.

Mad Cow Disease 袁聖甯黃竹瑄鄧雯心. What is Mad Cow Disease ? A kind of transmissible spongiform encephalopathies (TSE) Occurs in many mammals, including human.

Are humans susceptible?

Presumptive Transfusion Transmissions of vCJD: Introduction to Consideration of Current FDA-recommended Safeguards FDA TSE Advisory Committee 16 th Meeting.

VARIANT CJD AN UPDATE DR. HESTER WARD National CJD Surveillance Centre Edinburgh, UK

Hepatitis B: Epidemiology

Prion diseases or transmissible spongiform encephalopathies (TSEs) rare progressive neurodegenerative disorders that affect both humans and animals. They.

1 Transmissible Spongiform Encephalopathies. 2 Kuru Since the early 1900’s the Fore people of New Guinea have honored their dead by cooking and consuming.

Bovine Spongiform Encephalopathy Luke VanNatter Carrie Pell Amy Richwine Scott Inskeep Kristina Anderson.

Prions Alicia Arguelles, Jerry Wang May 4, What are prions? proteinaceous infectious particle an infectious agent made only of protein, containing.

Mad Cow Disease. Effects of Mad Cow disease Mad cow disease, or bovine spongiform encephalopathy (BSE), is a fatal brain disorder that occurs in cattle.

CLINICAL ASPECTS OF BIOCHEMISTRY NEURODEGENERATIVE DISEASES Prion diseases Alzheimer's disease.

Prion Diseases CMED 526/EPI May 6 th, 2009 Robert Harrington, DVM, PhD USDA – Agricultural Research Service UW – Dept. of Comparative Medicine

Babesiosis 1 st Quarter 2011 DIDE Training Jonah Long, MPH 1.

Transmissible Spongiform Encephalopathies Advisory Committee 23 rd Meeting Gaithersburg, MD – August 1, 2011 CJD and vCJD Donor Policies: Blood and Blood.

Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.

Prion Diseases Microbes and Society Fall What is a Prion? Prion- small proteinaceous infectious particles which resist inactivation by procedures.

FTD Family Members Study & Post Mortem Study Alyson Negreira MGH Frontotemporal Disorders Unit.

Evolution of the Mad Cow Disease in the United States Denish Moorthy, Eugene Shubnikov, Ron LaPorte The Supercourse Network of the Global Health University.

The Precautionary Principle Managing theoretical risks in public health.

PRION DISEASE & PENTOSAN POLYSULPHATE IN THE UK Richard Knight NCJDSU University of Edinburgh Scotland.

Transmissible Spongiform Encephalopathies Ryan Maddox, MPH Creutzfeldt-Jakob Disease Surveillance Unit Division of Viral and Rickettsial Diseases National.

HTLV-1 Associated Myelopathy Diagnosis and Treatment

Second case of variant CJD in Canada: case report and implications for assessment of geographic risk Michael B. Coulthart, PhD Director, Canadian CJD Surveillance.

The Pathological Protein, Chapters 8-9 Rhiannon Aguilar HONR299J March 27, 2014.

Prions: Proteins Gone Bad

BRAIN TRUST Nisha Pawar HONR 299J Spring CHAPTER 16—CLUSTERING  Current CDC position: sporadic CJD has nothing to do with tainted meat (only variant.

Fondazione IRCCS – Istituto Neurologico “Carlo Besta” Milano Gerstmann-Sträussler-Scheinker disease Fabrizio Tagliavini.

HERPES SIMPLEX ENCEPHALITIS ENCEPHALITIS M.RASOOLINEJAD, MD DEPARTMENT OF INFECTIOUS DISEASE TEHRAN UNIVERCITY OF MEDICAL SCIENCE.

Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.

The Swiss Population In 2001 Resident population: 7,258,500 Population density: 176 per Km 2 Foreign nationals: 20.1% (~1,460,000) Excess of births over.

 Foreign Sources of Infection To − Vi Nguyen. Foreign Infection  Preventable environmental source of infection  Remove infectious material, epidemic.

Is for Epi Epidemiology basics for non-epidemiologists.

12 August 2003 CJD Update Latest facts, figures & findings Jonathan P Clewley TSE Unit, Virus Reference Division, Centre for Infections 20 May 2005.

19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist CHIRON Submission To FDA TSE Advisory Committee Meeting.

Mad Cow Disease Making sense of the headlines by Trevor Murdock.

RISK COMMUNICATION APPROACH TSEAC 15 December 2006 Mark Weinstein, Ph.D. FDA, Center for Biologics Evaluation and Research.

Variant CJD and Plasma Products Risk assessment methods, assumptions and public health actions in the UK Kate Soldan & Anna Molesworth February 2005 Communicable.

Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;

Prions “Scrapie” “mad cow disease” Nobel Prize 1997

Microbes and Diseases Chapter 02. CREUTZFELDT-JAKOB DISEASE Prion.

Preliminary Risk Assessment Model for U.S. Plasma Derivatives and vCJD Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center for Biologics.

Risk Assessment: Questions to the Committee 1.What estimate(s) should be used to reflect the prevalence of vCJD in the U.K.? Proposal: We propose using.

Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.

VCJD World situation and Updates RG Will National CJD Research and Surveillance Unit Edinburgh, UK TSEAC meeting 1 st August 2011.

Blood-borne vCJD risk: in UK and other European populations Sheila M. Bird MRC Biostatistics Unit, CAMBRIDGE.

Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.

David M. Asher, MD Division of Emerging & Transfusion-Transmitted Diseases Office of Blood Research & Review Center for Biologics Evaluation & Research.

Slide 1 "CJD Lookback Study" (Research Study to Assess the Risk of Blood Borne Transmission of CJD) American Red Cross Blood Services TSEAC October 14,

FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.

TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,

Creutzfeldt-Jakob Disease Atif Chohan & Alex Brown.

Introduction to Pathophysiology Dr. Manzoor Ahmad Mir Assistant Professor (Immunopatholgy) College of Applied Medical Sciences Majmaah University.

RABIES Rabies belongs to Rhabdovirus It is the only human Rhabdovirus It is bullet-shaped, enveloped, helical, single stranded,

Prion diseases (transmissible spongiform encephalopathies) Dr. Mohammad Shakeeb, MD Specialist in clinical pathology/Microbiology and immunology.

(Bovine spongiform encephalopathy)

Bovine Spongiform Encephalopathy Variant Creutzfeldt-Jakob disease

Brain Trust Chapt 22: Origins

Natural History of Disease

Western blot analysis of skin tissue from CJD and non-CJD patients

Presentation transcript:

CJD Overview Bob Will, National CJD Surveillance Unit, Edinburgh, UK Associazione Italiana Encefalopatie da Prion Milano 3 Ottobre 2009

Science 1968

Questions What is the origin of infection in CJD? Is there a link to scrapie in sheep? What are the clinical and pathological characteristics of CJD? What are the epidemiological characteristics of CJD?

SYSTEMATIC STUDIES OF CJD WORLDWIDE

DISTRIBUTION OF SPORADIC CJD IN THE UK:

AUTHORMETHODRISK FACTORS Bobowick et al. (1973)38 “selected” cases; healthy controls.None. Kondo & Kuroiwa (1982)Population study: 60 cases, healthy controls trauma in males. Kondo (1985)88 autopsied cases; autopsied controls organ resection. Davanipour et al (1985)26 cases; 40 controlstrauma or surgery to head or neck; other trauma; surgery needing sutures; tonometry Davanipour et al (1985)26 cases; 40 controlsroast pork, ham, underdone meat, hot dogs. Davanipour et al (1985)26 cases; 40 controlscontact with fish, rabbits, squirrels. Harries-Jones et al (1980)92 cases; 184 controlsHerpes Zoster; keeping cats; contact with pets other than cats/dogs; dementia in family Van Duijn et al (1998)405 cases; 405 controlsconsumption of raw meat; consumption of brain; frequent exposure to leather products, exposure to fertilizer consisting of hoof and horn. Collins et al (1999)241 cases; 784 controlsnumber of surgical procedures; residence or employment on a farm or market garden. Ward et al (2002)326 cases; 326 controlssurgery, especially in females; ear piercing, psychiatric consultation. SIGNIFICANT RISK FACTORS IN CONTROLLED STUDIES

HUMAN TSEs (Prion diseases HUMAN TSEs (Prion diseases

SPORADIC CJD : EEG PERIODIC TRIPHASIC DISCHARGES 60-80% SENSITIVITY (TESTING POLICY) ? SPECIFICITY (? 74%) (CONTEXT DEPENDENT) ‘SUBJECTIVITY’ OF REPORTING NO EEG CRITERIA PROSPECTIVELY VALIDATED IN LARGE NUMBERS OF CASES

CSF Analysis Dr Alison Green, The National CJD Surveillance Unit ECDC funded meeting, 10 th March 2009 sCJD AD vCJD SpCJD Western Blot

MRI brain scan in sporadic CJD

MRI brain scan in variant CJD

IATROGENIC CREUTZFELDT-JAKOB DISEASE WORLDWIDE Mode of infection No. of patients Agent entry into brain Mean incubation period (range) Clinical signs on presentation Corneal transplant2Optic nerve18, 320 moDementia, cerebellar Stereotactic EEG2Intra-cerebral16, 20 moDementia, cerebellar Neurosurgery4Intra-cerebral17 mo (12-28)Visual/dementia/cerebellar Dura mater graft209Cerebellar surface11 yr (1.5-23)Cerebellar (visual, dementia) Growth hormone203Hematogenous(?)15 yr (4-36)Cerebellar Gonadotrophin4Hematogenous (?)13 yr (12-16)Cerebellar Blood transfusion3 (+1)Hematogenous6.5, 7.5, 8.5 yrSensory, psychiatric

DURA MATER CASES WORLDWIDE SHOWN BY YEAR OF OPERATION AND YEAR OF ONSET OF SYMPTOMS FOR CJD Mean incubation period from operation to onset of symptoms: 6.8 years (range 1-16)

THE HUMAN PRION PROTEIN GENE Mutations and polymorphisms Clinical diagnosis Screening of family members Pre-natal testing Influence on phenotype

‘BSE posed the greatest political and economic challenge to the EU since its foundation’ The specified bovine offal ban UK Dec 1989/ Jan1990 The UK BSE epidemic

DIFFERENCES BETWEEN SPORADICAND VARIANT CJD

AGE AT DEATH FOR SPORADIC CJD CASES AND vCJD CASES BY 5-YEAR AGE GROUP Age Group Number of cases

Results Temporal distribution of vCJD cases in France and UK According to the year of onset, the number of vCJD cases in France reached a peak of incidence in 2004, five years after the peak observed in the UK in 1999

YEAR OF ONSET OF ILLNESS OF vCJD WORLDWIDE Year Onset UKFranceIrelandItalyUSACanadaSaudi Arabia JapanNether -lands PortugalSpain Total

CHARACTERISTICS OF TSEs Prolonged incubation periods. Uniformly fatal neurological diseases. Causal agents (prions) resistant to sterilisation. No serological test for infection. Infection may be present in tissues (LRS) during the incubation period.

Donation (RBC) Donor onset Donor death vCJD case (Case 1) vCJD case (Case 3) Transfusion to recipient Donation 1 (RBC) Donor onset Donor death Recipient onset Recipient death Transfusion to recipient Recipient onset Recipient death Pre-clinical infection (Case 2) Donor onset Donor death Donation (RBC) RBC=red blood cells Transfusion to recipientRecipient death Years shown by quarter vCJD case (Case 4) Donation 2 (RBC) Transfusion to recipient Donor onset Donor death Recipient onset Recipient death

There is no evidence of transmission of any form of CJD through: Social contact Treating minor injuries Occupational contact Maternal transmission Sexual transmission General surgery

EUROCJD & NEUROCJD Joint Meeting Lake Garda, Italy May 2003